Christine Blazynski, PhD
Senior Product Manager, Special Projects
25+ years of experience
She joined Pharma Intelligence through the Citeline acquisition in late 2006. At that time, Christine headed editorial operations, product evolution, new product development and content strategy. She has written numerous white papers on trends in clinical development, pipeline rationalization, clinical trial terminations and business strategy using the wealth of data offered by Pharma Intelligence’s intelligence products.
Christine's educational background is in biochemistry and biophysics. She earned a PhD from Purdue University and BS degree from the University of Scranton. Christine was on the faculty at Washington University School of Medicine in the departments of Biochemistry & Molecular Biophysics, Ophthalmology, and Anatomy & Neurobiology. She Ieft academia to pursue a career in market research and business analysis first at Decision Resources and then with Citeline/Pharma Intelligence.
In Christine's role in product management, her goal is to listen to clients’ and non-clients’ needs for better approaches to connecting data across Pharma Intelligence.
Christine Blazynski, PhD 27 Nov 2020
The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, this article reviews trial benchmarks within the active oncology therapeutic area. Industry-sponsored clinical trials across all oncology indications covered by Informa Pharma Intelligence’s Trialtrove were assessed, comparing metrics by company size based on pharma sales, and the identical benchmarks for breast cancer and rare cancers were also analyzed.
By Christine Blazynski, PhD 19 Oct 2018
As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.
Topic Clinical Trials
By Christine Blazynski, PhD 29 May 2017
Company pipeline depictions are snapshots that illustrate, at that point in time, where a therapeutic candidate sits in terms of development stage for a specific therapy area or disease.
Christine Blazynski, PhD 12 Dec 2014
Over the past year, Citeline has been monitoring 360 public Chinese hospitals.
By Christine Blazynski, PhD 23 Apr 2014
In 2005, the International Committee of Medical Journal Editors (ICMJE) required registration of trials in a public registry at or before the time of first patient enrollment as a condition for publication in their member journals.
Topic Clinical Trials Blog